A bill to amend the Federal Food, Drug, and Cosmetic Act to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases.

Bill 118 s 4583, also known as the "Rare Pediatric Disease Priority Review Voucher Program Reauthorization Act of 2021," aims to amend the Federal Food, Drug, and Cosmetic Act. The main purpose of this bill is to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers. These vouchers are designed to incentivize pharmaceutical companies to develop treatments for rare pediatric diseases.

The bill seeks to encourage the development of treatments for rare pediatric diseases by providing pharmaceutical companies with priority review vouchers. These vouchers can be used to expedite the review process for other drugs developed by the company. This incentive is intended to spur innovation and investment in treatments for rare pediatric diseases, which often do not receive as much attention or funding as more common diseases.

By extending the authority of the Secretary of Health and Human Services to issue these vouchers, the bill aims to continue supporting the development of treatments for rare pediatric diseases. This reauthorization of the Rare Pediatric Disease Priority Review Voucher Program is seen as a crucial step in addressing the unmet medical needs of children with rare diseases. Overall, Bill 118 s 4583 is focused on promoting the development of treatments for rare pediatric diseases through the use of priority review vouchers. This legislation is aimed at encouraging pharmaceutical companies to invest in research and development for these often overlooked diseases, ultimately benefiting children who are in need of effective treatments.